AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25129453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment buddying
Number of subjects: 294
Study 25129453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment buddying with PAS
Number of subjects: 294
Study 23312695 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH‐nf 1000 U (with an additional 1000 U given 1 hour later if needed)
Number of subjects: 46
Study 23312695 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH‐nf 1000 U twice weekly
Number of subjects: 46
Study 23312695 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH‐nf use
Number of subjects: 46
Study 23312695 — intervention group
Group type: COMPARATOR
Intervention: C1 INH‐nf
Number of subjects: 46
Study 21200360 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine
Number of subjects: 784
Study 21200360 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-DT vaccine (Control)
Number of subjects: 784
Study 21200360 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT/10 vaccine
Number of subjects: 784
Study 18086463 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA supplement (eicosapentanoic acid (EPA) plus docosahexanoic acid (DHA), 2.2 mg/day in a 3:2 ratio)
Number of subjects: 21
Study 18086463 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil placebo
Number of subjects: 21
Study 18086463 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label PUFA administration
Number of subjects: 21
Study 16778659 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-blade speculum cannula for minimally invasive lumbar microdiscectomy
Number of subjects: 52
Study 12694968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclosure of the peritoneum
Number of subjects: 280
Study 12694968 — intervention group
Group type: COMPARATOR
Intervention: Closure of the peritoneum
Number of subjects: 280
Study 10673513 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m(2), intravenous bolus every 3 weeks
Number of subjects: 331
Study 10673513 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m(2), 3-hour infusion every 3 weeks
Number of subjects: 331
Study 10673513 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (second-line therapy after cross-over)
Number of subjects: 331
Study 10673513 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (second-line therapy after cross-over)
Number of subjects: 331
Study 10673513 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 331
Study 10673513 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 331
Study 8926071 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei‐rEPA
Number of subjects: 192
Study 8926071 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri‐rEPA
Number of subjects: 192
Study 8926071 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a‐rEPA
Number of subjects: 192
Study 1671726 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study 6548867 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy for 1 year (group A)
Number of subjects: 56
Study 6548867 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy for 1 year and postoperative radiation therapy (group B)
Number of subjects: 56
Study 29504415 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (12.5 and/or 25 mg)
Number of subjects: 2135
Study 29504415 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Usual care
Number of subjects: 2135
Study 29504415 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (all doses)
Number of subjects: 2135
Study 27773802 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) 2.8g three times per day for 28 days
Number of subjects: 64
Study 25118129 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation (four, two-hour biweekly multifamily psychoeducation sessions) plus treatment-as-usual for the patient (consultation by physicians)
Number of subjects: 0
Study 25118129 — intervention group
Group type: COMPARATOR
Intervention: Counseling for the family (one counseling session from a nurse) plus treatment-as-usual for the patient
Number of subjects: 0
Study 23571150 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-fluorouracil (HD-FU)
Number of subjects: 1601
Study 23571150 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus 5-fluorouracil regimen (Mayo Clinic)
Number of subjects: 1601
Study 20967993 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin (vesikar) 5 mg/day
Number of subjects: 40
Study 20967993 — intervention group
Group type: COMPARATOR
Intervention: combined treatment
Number of subjects: 40
Study 17581772 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCheck intervention (electronic medication safety messages)
Number of subjects: 267
Study 16246621 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (viewing a series of educational videotapes and case scenarios)
Number of subjects: 112
Study 16246621 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 112
Study 12821733 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days
Number of subjects: 129
Study 12821733 — intervention group
Group type: COMPARATOR
Intervention: Matching IV and oral placebos
Number of subjects: 129
Study 11035355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg daily)
Number of subjects: 50
Study 11035355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9375752 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (0.3-3.0 microg/kg/d, s.c.) and epo (60-300 U/kg/d, s.c.) for at least 10 weeks
Number of subjects: 98
Study 9375752 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF plus epo
Number of subjects: 98
Study 9375752 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive scoring system based on pre-treatment serum epo levels and RBC transfusion need
Number of subjects: 98
Study 8385526 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ceiling dose 100 mg)
Number of subjects: 25
Study 8385526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ceiling dose 40 mg)
Number of subjects: 25
Study 8385526 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Lisinopril
Number of subjects: 25
Study 2883830 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 10
Study 2883830 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 10
Study 2883830 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg
Number of subjects: 10
Study 2883830 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 10
Study 2883830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31415443 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 4‐min high‐intensity interval training at 90% of HRMAX (4HIIT group; n = 32)
Number of subjects: 121
Study 31415443 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐min moderate‐intensity continuous training at 70% of HRMAX (MICT group; n = 35)
Number of subjects: 121
Study 31415443 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 × 1‐min HIIT at 100% of HRMAX (1HIIT group; n = 32)
Number of subjects: 121
Study 31415443 — intervention group
Group type: COMPARATOR
Intervention: No exercise control group (CONT; n = 22)
Number of subjects: 121
Study 31415443 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HIIT, MICT, and 1HIIT groups
Number of subjects: 121
Study 30027438 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 407
Study 30027438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 27902608 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ulnar artery compression (UC)
Number of subjects: 446
Study 27902608 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 446
Study 24788563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib alone (20 mg/day)
Number of subjects: 22
Study 24788563 — intervention group
Group type: COMPARATOR
Intervention: Cediranib plus dasatinib (100 mg/day)
Number of subjects: 22
Study 23015750 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT) - 6 sessions
Number of subjects: 57
Study 23015750 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI) - single session
Number of subjects: 57
Study 20837956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (20 mg daily)
Number of subjects: 2434
Study 20837956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2434
Study 18407016 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Slick elastomeric rings
Number of subjects: 20
Study 18407016 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastomeric rings
Number of subjects: 20
Study 17876372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil (Idhayam gingelly oil) used as the only edible oil for 45 days
Number of subjects: 50
Study 14644892 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8206
Study 11004026 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Number of subjects: 40
Study 11004026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block
Number of subjects: 40
Study 8633488 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 41
Study 8633488 — intervention group
Group type: COMPARATOR
Intervention: Control (H2 blocker for 2 months, then intermittent antisecretory agents for up to 1 yr)
Number of subjects: 41
Study 1319083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 1319083 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of positive lymph nodes
Number of subjects: 0
Study 1319083 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of anaplasia
Number of subjects: 0
Study 2859200 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 32
Study 2859200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30980122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 1 g/day
Number of subjects: 10
Study 30980122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 2 g/day
Number of subjects: 10
Study 30980122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 3 g/day
Number of subjects: 10
Study 30284393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac (Nevanac, 1 mg/ml) for 3 weeks
Number of subjects: 95
Study 30284393 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free diclofenac (Dicloabak, 1 mg/ml) for 3 weeks
Number of subjects: 95
Study 24731865 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention for 12 months
Number of subjects: 300
Study 24731865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHW intervention)
Number of subjects: 300
Study 22136324 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro with recombinant human hyaluronidase (rHuPH20)
Number of subjects: 21
Study 22136324 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin (RHI) with recombinant human hyaluronidase (rHuPH20)
Number of subjects: 21
Study 22136324 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro alone
Number of subjects: 21
Study 20414695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy (acute LDH, n = 20)
Number of subjects: 80
Study 20414695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy (chronic LDH, n = 20)
Number of subjects: 80
Study 20414695 — intervention group
Group type: COMPARATOR
Intervention: Hot-pack + placebo laser therapy (acute LDH, n = 20)
Number of subjects: 80
Study 20414695 — intervention group
Group type: COMPARATOR
Intervention: Hot-pack + placebo laser therapy (chronic LDH, n = 20)
Number of subjects: 80
Study 18403795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium rabeprazole 20 mg orally at 2100 h the night before surgery
Number of subjects: 117
Study 18403795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 117
Study 18511355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day vitamin K1
Number of subjects: 14
Study 18511355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day vitamin K1
Number of subjects: 14
Study 15184720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (Zyban)
Number of subjects: 78
Study 11686812 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B 3D Plaque Remover)
Number of subjects: 48
Study 11686812 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Crest Complete)
Number of subjects: 48
Study 9470865 — intervention group
Group type: EXPERIMENTAL
Intervention: New procedures
Number of subjects: 0
Study 9470865 — intervention group
Group type: COMPARATOR
Intervention: Established procedures
Number of subjects: 0
Study 9470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural treatment
Number of subjects: 0
Study 9470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation regimens for coronary stents
Number of subjects: 0
Study 9470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised studies
Number of subjects: 0
Study 9470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of large clinical series
Number of subjects: 0
Study 7929695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-1 alpha (3.0 micrograms/m2/day)
Number of subjects: 29
Study 7929695 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IL-1 alpha (0.1, 0.3, or 1.0 microgram/m2/day)
Number of subjects: 29
Study 7929695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-1 alpha
Number of subjects: 29
Study 7929695 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IL-1 alpha
Number of subjects: 29
Study 3282911 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg x 3 daily for patients <30 kg or 400 mg x 2 daily for patients >30 kg
Number of subjects: 54
Study 3282911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 4262
Study 29635419 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCG vaccine)
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in children with BCG-vaccinated mothers
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in children with non-BCG-vaccinated mothers
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in children born by cesarean section
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in other children (not born by cesarean section)
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in premature children
Number of subjects: 4262
Study 29635419 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine in children born at term
Number of subjects: 4262
Study 28560328 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-grid solar power
Number of subjects: 1281
Study 26923690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment and exercise therapy
Number of subjects: 52
Study 26923690 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment and exercise therapy
Number of subjects: 52
Study 26923690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 52
Study 25262458 — intervention group
Group type: EXPERIMENTAL
Intervention: StopAdvisor
Number of subjects: 4613
Study 25262458 — intervention group
Group type: COMPARATOR
Intervention: Information-only website
Number of subjects: 4613
Study 22034523 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint spirits inhalation
Number of subjects: 35
Study 22034523 — intervention group
Group type: COMPARATOR
Intervention: Placebo aromatherapy (inert placebo, green-colored sterile water)
Number of subjects: 35
Study 22034523 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy (intravenous ondansetron or promethazine suppositories)
Number of subjects: 35
Study 19733206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (0.06% chlorhexidine, pH 6.0, Periogard‐Colgate, Brazil)
Number of subjects: 12
Study 19733206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.61% green tea extract solution (OM24, 100% Camellia Sinensis leaf extract, catechin concentration: 30+/‐3%, pH 7.0, Omnimedica, Switzerland)
Number of subjects: 12
Study 19733206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste and electrical toothbrush (F)
Number of subjects: 12
Study 19733206 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control)
Number of subjects: 12
Study 17452070 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min training course for cardiopulmonary resuscitation and automated external defibrillator use
Number of subjects: 0
Study 17452070 — intervention group
Group type: COMPARATOR
Intervention: Traditional multi-hour Heartsaver-AED training
Number of subjects: 0
Study 15629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based reminder/recall letters (up to 3 letters)
Number of subjects: 5193
Study 15629993 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5193
Study 11907288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg daily for six weeks)
Number of subjects: 209
Study 11907288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 10206519 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital hearing aid with compression and noise reduction
Number of subjects: 27
Study 10206519 — intervention group
Group type: COMPARATOR
Intervention: Analogue reference aids
Number of subjects: 27
Study 7605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurons related to overt speech (Type A neurons) during verbal paired associates learning
Number of subjects: 49
Study 7605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurons not related to language or memory (Type D neurons) during exposure to unlearned word pairs
Number of subjects: 49
Study 7605928 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups of neurons during practice
Number of subjects: 49
Study 2404097 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant therapy
Number of subjects: 94
Study 2404097 — intervention group
Group type: COMPARATOR
Intervention: Sham (air) therapy
Number of subjects: 94
Study 850579 — intervention group
Group type: EXPERIMENTAL
Intervention: ACFUCY combination (Actinomycin‐D, 5‐fluorouracil, and cyclophosphamide)
Number of subjects: 108
Study 850579 — intervention group
Group type: COMPARATOR
Intervention: Melphalan
Number of subjects: 108
Study 850579 — intervention group
Group type: EXPERIMENTAL
Intervention: ACFUCY combination
Number of subjects: 108
Study 31610152 — intervention group
Group type: EXPERIMENTAL
Intervention: White women before menopause
Number of subjects: 94
Study 31610152 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women before menopause
Number of subjects: 94
Study 31610152 — intervention group
Group type: EXPERIMENTAL
Intervention: White women postmenopause
Number of subjects: 94
Study 31610152 — intervention group
Group type: COMPARATOR
Intervention: Black women postmenopause
Number of subjects: 94
Study 30191995 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 286
Study 30191995 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 286
Study 27432356 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Classic (MTX + sulfasalazine + prednisone step-down from 60 mg)
Number of subjects: 379
Study 27432356 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Slim (MTX + prednisone step-down from 30 mg) high risk
Number of subjects: 379
Study 27432356 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Avant Garde (MTX + leflunomide + prednisone step-down from 30 mg)
Number of subjects: 379
Study 27432356 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX tight step-up (MTX-TSU)
Number of subjects: 379
Study 27432356 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Slim (low risk)
Number of subjects: 379
Study 25187182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain diary intervention measuring pain intensity, location, duration, affective ratings, and coping responses
Number of subjects: 95
Study 23869186 — intervention group
Group type: EXPERIMENTAL
Intervention: Echogenic needle (Group E)
Number of subjects: 90
Study 23869186 — intervention group
Group type: COMPARATOR
Intervention: Non-echogenic needle (Group N)
Number of subjects: 90
Study 23869186 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-echogenic needle with nerve stimulator (Group NS)
Number of subjects: 90
Study 21867532 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES) Therapy
Number of subjects: 41
Study 21867532 — intervention group
Group type: COMPARATOR
Intervention: Control (non-NMES)
Number of subjects: 41
Study 19152514 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ALA-based photodynamic therapy (PDT) applied for 4 hours, followed by excimer-dye laser exposure at 630 nm at a dose of 50 J/cm² three times at 7-day intervals.
Number of subjects: 30
Study 17904980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancies (preeclampsia or gestational hypertension) at 35 weeks
Number of subjects: 4293
Study 17904980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancies (preeclampsia or gestational hypertension) at 36 weeks
Number of subjects: 4293
Study 17904980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancies (preeclampsia or gestational hypertension) at 37 weeks
Number of subjects: 4293
Study 15383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-second wait time
Number of subjects: 0